It also decreases phosphorylation of PI3K, AKT, and mTOR, indicating that the knockdown of this lncRNA-HOTAIR attenuated the resistance of BC cells to doxorubicin through inhibition of the PI3K/AKT/mTOR signaling pathway. The gene discussed is AKT1; the disease is breast cancer.